<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931225</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191047</org_study_id>
    <nct_id>NCT04931225</nct_id>
  </id_info>
  <brief_title>LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS)</brief_title>
  <acronym>MILANOS</acronym>
  <official_title>LANdiolol MIcrocirculatory Effects During Septic chOc</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the effect of continuous intravenous Landiolol&#xD;
      injection (from 0.5 to 10 µg/kg/min during 12 hours ) up to a 15% decrease in Heart Rate (HR)&#xD;
      on microcirculatory vascular reactivity vs. usual tachycardia management and evaluate the&#xD;
      hemodynamic effects of Landiolol vs. usual management in patients with septic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, prospective, randomized, open label, evaluation of the efficacy of&#xD;
      continuous intravenous Landiolol injection up to a 15% decrease in HR on microcirculatory&#xD;
      vascular reactivity vs. usual tachycardia management.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      A monocentric, open-label, randomised, superiority clinical trial&#xD;
&#xD;
      Sample size :&#xD;
&#xD;
      44 patients, 22 in each group&#xD;
&#xD;
      Treatments groups:&#xD;
&#xD;
      Continuous intravenous Landiolol injection ( from 0.5 to 10 µg/kg/min during 12 hours ) up to&#xD;
      a 15% decrease in HR on microcirculatory vascular reactivity vs usual tachycardia management&#xD;
&#xD;
      Treatment duration :&#xD;
&#xD;
      24 hours&#xD;
&#xD;
      Assessement:&#xD;
&#xD;
      Landiolol (Rapibloc)'s perfusion will be started at T0 at 0.5 mcg/kg/min and increased by 0.5&#xD;
      mcg/kg/min every 30 minutes in order to achieve a 15% (T1) decrease in HR, within the limit&#xD;
      of 10 mcg/kg/min. Then the dosage will be maintained for 2 hours (T2) then the drug will be&#xD;
      stopped gradually over 2 hours.&#xD;
&#xD;
      Maximum duration of Landiolol infusion will be 12 hours.&#xD;
&#xD;
      No interim analysis is planned. Analysis will be performed at the end of the study after data&#xD;
      review and freezing of database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of decrease in heart rate (HR) on microcirculatory vascular reactivity</measure>
    <time_frame>24 hours</time_frame>
    <description>The objectives of this study are to evaluate the effect of continuous intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours ) up to a 15% decrease in HR on microcirculatory vascular reactivity vs. usual tachycardia management in patients with septic shock.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac flow</measure>
    <time_frame>24 hours</time_frame>
    <description>Measure of the cardiac flow to evaluate the hemodynamic effects of Landiolol vs. usual tachycardia management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>marbling score</measure>
    <time_frame>24 hours</time_frame>
    <description>Measure of the marbling score to evaluate the effects of Landiolol vs. usual tachycardia management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin recoloration time</measure>
    <time_frame>24 hours</time_frame>
    <description>Measure of skin recoloration time to evaluate the effects of Landiolol vs. usual tachycardia management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial lactate clearance</measure>
    <time_frame>24 hours</time_frame>
    <description>Measure of sarterial lactate clearance to evaluate the effects of Landiolol vs. usual tachycardia management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Systemic and endothelial inflammation parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluate the hemodynamic effects of Landiolol vs. usual tachycardia management on Systemic and endothelial inflammation parameters: Plasma cytokines (Procartaplex) VCAM-1 (vascular endothelial cell adhesion molecule), Soluble Endocan (ELISA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Landiolol injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual tachycardia management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment, usual tachycardia management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Landiolol</intervention_name>
    <description>Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.</description>
    <arm_group_label>Landiolol injection</arm_group_label>
    <other_name>Rapibloc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sinus tachycardia not compensatory, if the doctor considers that the heart rate&#xD;
             acceleration should be treated.&#xD;
&#xD;
          -  The study will be carried out in&#xD;
&#xD;
          -  reanimated and stabilized septic shock defined as:&#xD;
&#xD;
               -  Septic shock is tachycardic (HR&gt;100/min) patients with sepsis (suspected&#xD;
                  infection + 2 SOFA points) according to the latest international definition and&#xD;
                  the need to receive noradrenaline to maintain an average blood pressure above 65&#xD;
                  mmHg&#xD;
&#xD;
               -  Patient supported for at least 6 hours, necessary for diagnostic management and&#xD;
                  hemodynamic optimization according to international standards and for less than&#xD;
                  24 hours to limit confounding factors related to prolonged reanimation (sedation)&#xD;
                  and empowerment of organ failure in general and vascular in particular.&#xD;
                  Hemodynamic stabilization will be defined as the absence of increased doses of&#xD;
                  norepinephrine in the previous two hours to limit the risk of hypotension induced&#xD;
                  by Landiolol infusion.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Patient (or family member) informed consent signature or emergency consent&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Patients treated with the following bradycardizing drugs:&#xD;
&#xD;
          -  Digitalis&#xD;
&#xD;
          -  Bradycardizing calcium channel blockers&#xD;
&#xD;
          -  Cordarone&#xD;
&#xD;
          -  Other beta-blocker&#xD;
&#xD;
          -  Hypersensitivity to Landiolol or to one of its excipients (Mannitol E421, sodium&#xD;
             hydroxide)&#xD;
&#xD;
          -  Sinus disease&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Decompensated heart failure when considered unrelated to arrhythmia&#xD;
&#xD;
          -  Pregnant or nursing woman,&#xD;
&#xD;
          -  Participation in another interventional research involving the human person or being&#xD;
             in the exclusion period following a previous research involving the human person, if&#xD;
             applicable&#xD;
&#xD;
          -  Ward or curative patient&#xD;
&#xD;
          -  Moribund patient&#xD;
&#xD;
          -  Estimated life expectancy less than 1 month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hafid AIT-OUFELLA, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hafid AIT-OUFELLA, Professor</last_name>
    <phone>01 49 28 23 15</phone>
    <email>hafid.aitoufella@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intensive care department, Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hafid AIT-OUFELLA, Professor</last_name>
      <phone>01 49 28 23 15</phone>
      <email>hafid.aitoufella@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Landiolol</keyword>
  <keyword>Microcirculatory effects</keyword>
  <keyword>Heart rate</keyword>
  <keyword>Hemodynamic effects</keyword>
  <keyword>Microvascular reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Landiolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

